Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection

Clinical trial NCT02201953 · COMPLETED

Trial details

NCT number: NCT02201953
Sponsor: Gilead Sciences
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Hepatitis C Virus Infection

Start date: 2014-07-01
Primary completion: 2015-09-01
Enrollment: 558

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.